(Q38239192)

English

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

scientific article published on 12 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

0 references

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Michael J. Sorich

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Michael D Wiese

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ganessan Kichenadasse

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ross A. McKinnon

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Christos S Karapetis

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

M J Sorich

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

M D Wiese

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

A Rowland

3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

G Kichenadasse

4

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

R A McKinnon

5

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

C S Karapetis

6

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

12 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

13-21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25115304%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU378

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38239192&oldid=2170532373"